EMA launches new advisory group on vaccine confidence

WHY IT MATTERS

For patients with rare diseases who may be immunocompromised or at higher risk from vaccine-preventable infections, vaccine confidence directly affects community protection through herd immunity and the safety of vaccines available to them.

The European Medicines Agency (EMA) created a new advisory group to address vaccine hesitancy—when people are unsure about getting vaccines. The group will meet four times a year and includes doctors, patient representatives, and other experts. Their goal is to help the EMA understand why people distrust vaccines and find ways to rebuild confidence in vaccine safety.

Source: European Medicines Agency (EMA) Description: EMA has set up a new advisory group on vaccine confidence, which will advise the Agency on issues related to vaccine hesitancy and help guide its actions to increase science…, "Vaccine hesitancy is a growing global threat to public health. When public trust declines, infectious diseases can reemerge, putting lives at risk. EMA has a vital…, The advisory group on vaccine confidence will meet quarterly. It includes academics, representatives of healthcare professionals, medical societies and patie Published: 2026-04-29T10:00:00.000Z Note: EMA announcements cover medicines approved in the EU. Orphan designations may not yet be available in the US.